下载 Oncology Nursing Drug Handbook - v3.5.13

您听说过Oncology Nursing Drug Handbook - v3.5.13或Medical PG, FMGE Preparation - PrepLadder, iDentist Dental practice management, MCQ Abubakr (ASU), ALAT, Pacify, Inject App，是类别医疗中最酷的应用之一。

当然，您知道并非所有游戏或应用程序都兼容所有手机。游戏或应用程序有时在您的设备上不可用，这取决于系统版本。Android操作系统，屏幕分辨率或国家/地区Google Play允许访问。这就是APKPanda提供Android APK文件供您下载且不遵守这些限制的原因。>
Oncology Nursing Drug Handbook - v3.5.13的最新版本为3.5.13，发行日期为2020-06-25，大小为8.4 MB。由Skyscape Medpresso Inc开发，Oncology Nursing Drug Handbook - v3.5.13至少需要Android版本Android 5.0+。因此，如有必要，您必须更新手机。

负载量很大，大约有1000次下载。您可以根据需要更新已单独下载或安装在Android设备上的应用程序。更新应用程序使您可以访问最新功能，并提高应用程序的安全性和稳定性。

Written especially for nurses caring for patients with cancer, the 2020-2021 Oncology Nursing Drug Handbook uniquely expresses drug therapy in terms of the nursing process: nursing diagnoses, etiologies of toxicities, and key points for nursing assessment, intervention, and evaluation. This essential reference provides valuable information on effective symptom management, patient education, and chemotherapy administration.

DESCRIPTION
Completely revised and updated, the 2020-2021 Oncology Nursing Drug Handbook includes separate chapters on molecular and immunologic/biologic targeted therapies. These chapters provide fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer. It also offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for drugs recently approved by the FDA.

Key Features

- Provides valuable information on effective symptom management, patient education, and chemotherapy administration.
- Completely revised and updated, includes separate chapters on molecular and immunologic/biologic targeted therapies
- Provides fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer
- Offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for recently FDA approved drugs
- New drugs include: apalutamide (Erleada™), calaspargase pegol-mknl (Asparlas™), Daunorubicin and cytarabine liposome for injection (Vyxeos®), glucarpidase (Voraxaze®), alpelisib (Piqray®), binimetinib (Mektovi®), dacomitinib (Vizimpro®), Duvelisib (Copiktra®), encorafenib (Braftovi®), erdafitinib (Balversa™), lorlatinib (Lorbrena®), anakinra (Kineret®), baricitinib (Olumiant®), sarilumab (Kevzara®), aprepitant injectable emulsion (Cinvanti®), granisetron hydrochloride extended-release injection (Sustol®), letermovir (Prevymis™), omadacycline (Nuzyra™), meropenem/vaborbactam (Vabomere™), Plazomicin (Zemdri™), baloxavir marboxil (Xofluza™), imipenem/cilastatin sodium/relebactam (Recarbrio™), eravacycline (Xerava™), delafloxacin (Baxdela™)

Faster download with slow internet connectivity